This conference welcomes a distinguished faculty summarizing the latest data presented at GI ASCO 2024.
Welcome:
Internists, family practitioners, surgeons, medical and radiation oncologists and other physicians, nurses, and allied health professionals.
Objectives:
- Recognize the continued increasing incidence of HCC worldwide mainly due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Review recent studies and updates of immunotherapy and systemic therapy in metastatic Esophagogastric Cancer.
- Identify the role of single agent vs. combined immunotherapy in metastatic dMMR mCRC and metastatic anal cancer.
- Date: April 26, 2024
- Time: 9:00am to 12:00pm
- Location: Virtual
- Credits: 3 AMA PRA Category 1 Credits™
Atlantic Health System is accredited by the Medical Society of New Jersey to provide continuing medical education for physicians. Atlantic Health System designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AGENDA
| Time | Topic | Speaker |
| 9:00am - 9:05am | Welcome | Angela Alistar, MD, Medical Director, Gastrointestinal Oncology Phase 1 Medical Director AHS |
| 9:05am - 10:00am | Hepatobiliary Practice Changes Updates | Ghassan Abou-Alfa, MD, MBA Professor, Weill Cornell College at Cornell University |
| 10:00am - 10:55am | Esophagogastric Cancer Updates | David Ilson, MD, PhD Gastrointestinal Oncology |
| 10:55 - 11:50am | Colorectal & Anal Cancer -Practice Changes Updates | Cathy Eng, MD, FACP, FASCO David H. Johnson Endowed Chair in Surgical and Medical Oncology |
| 11:50 am | Closing Remarks | Angela Alistar, MD Phase 1 Medical Director |
For more information on Atlantic Health System Classes and Events, please call 1-800-247-9580 or email us >